Etanercept as adjunctive treatment for acute Kawasaki disease: study design and rationale. Am Heart J 2011 Mar;161(3):494-9
Date
03/12/2011Pubmed ID
21392603DOI
10.1016/j.ahj.2010.12.003Scopus ID
2-s2.0-79952377060 (requires institutional sign-in at Scopus site) 37 CitationsAbstract
BACKGROUND: Kawasaki disease (KD) is a multisystem vasculitis affecting coronary arteries in children. Patients, refractory to standard treatment with intravenous immunoglobulin and aspirin, show higher rates of coronary artery dilation. Early tumor necrosis factor α receptor antagonism in KD may provide effective adjunctive therapy.
STUDY DESIGN: The EATAK trial is a multicenter, double-blind, randomized, and placebo-controlled trial intended to assess the efficacy of etanercept in reducing the intravenous immunoglobulin refractory rate during treatment of acute KD. Each arm will enroll 110 patients who will receive 3 doses of study drug over 2 weeks in conjunction with standard therapy. Coronary artery dilation parameters will serve as secondary end points.
DISCUSSION: The EATAK trial will test a new paradigm for treatment of acute KD involving tumor necrosis factor α antagonism by etanercept.
Author List
Portman MA, Olson A, Soriano B, Dahdah N, Williams R, Kirkpatrick EAuthor
Edward C. Kirkpatrick DO Professor in the Pediatrics department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
Coronary VesselsDilatation, Pathologic
Endpoint Determination
Etanercept
Humans
Immunoglobulin G
Immunoglobulins, Intravenous
Immunologic Factors
Receptors, Tumor Necrosis Factor
Research Design